We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Unexplained Illness Puts Pathogen Discovery to Test

By LabMedica International staff writers
Posted on 05 Sep 2018
High-throughput sequencing can provide insights into epidemiology and medicine through comprehensive surveys of viral genetic sequences in environmental and clinical samples.

Characterization of the viruses found in the blood of febrile patients provides information pertinent to public health and diagnostic medicine. More...
Polymerase chain reaction (PCR) and culture have historically played an important role in clinical microbiology; however, these methods require a targeted approach and may lack the capacity to identify novel or mixed viral infections.

An international team of scientists led by those at the University of Columbia (New York, NY, USA) employed two complementary methods to address challenges in diagnostic virology: a method for positive selection of the viral template prior to sequencing and a simplified high-throughput sequencing (HTS) analysis pipeline. The team used 12 plasma samples from patients with unexplained febrile illness were used for comparative analysis. Samples were collected from a larger cohort of adults attending outpatient departments in Dar es Salaam, Tanzania, between August 2013 and April 2014, enrolled in an observational cohort to determine the causes of fever.

Malaria was excluded as a cause of fever in these patients following screening with a standard malaria rapid diagnostic test (mRDT) SD Bioline Malaria AG P.f., and the ultrasensitive mRDT Alere Malaria AG P.f., Korea. RNA and DNA were extracted and library preparations were made. RNA libraries for samples 1 to 6 were loaded on a HiSeq 4000 system using a multiplex of four samples per lane, while those from samples 7 to 12 were loaded on a HiSeq 2500 system using a multiplex of four samples per lane. All DNA libraries were loaded on a HiSeq 4000 system (multiplex of six samples per lane).

Sequencing methods compared in the study identified genetic sequences from Dengue virus, West Nile virus, HIV, human pegivirus, and Epstein Barr virus. However, unbiased high throughput sequencing required more extensive sample processing and bioinformatics analysis and 20-fold more sequences than VirCapSeq-VERT to achieve these results. VirCapSeq-VERT had better sensitivity; unbiased sequencing provided better coverage of genome termini. Together, these data demonstrate the utility of high-throughput sequencing strategies in outbreak investigations.

W. Ian Lipkin, MD, a professor and senior author of the study, said, “Whether in Tanzania or Texas, physicians everywhere are constrained by resources. VirCapSeq-VERT is proving to be very efficient way to shed light on medical mysteries so patients can get the treatment they need. From public health perspective, our method provides a cost-effective way to monitor emerging infectious diseases in order to guide prevention efforts.” The study was published on August 22, 2018, in the journal mSphere.

Related Links:
University of Columbia


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.